Endocrinology focuses on hormonal system and metabolic health. Learn about the diagnosis and treatment of diabetes, thyroid disorders, and adrenal conditions.
Send us all your questions or requests, and our expert team will assist you.
Accurate diagnosis and evaluation of pheochromocytoma is essential for preventing life‑threatening hypertensive crises and ensuring optimal surgical outcomes. This page is designed for international patients and referring physicians who need a clear, step‑by‑step overview of how the condition is identified, confirmed, and prepared for treatment at Liv Hospital. Worldwide, pheochromocytoma accounts for roughly 0.1% of cases of hypertension, yet up to 30% of patients remain undiagnosed until a crisis occurs. Understanding the clinical clues, laboratory work‑up, imaging strategies, and genetic considerations can dramatically improve safety and prognosis.
We will explore the full spectrum of the diagnostic pathway—from the first patient encounter to the final multidisciplinary plan—highlighting the expertise and technology available at our JCI‑accredited centre. Whether you are a patient seeking clarity or a clinician coordinating care, the information below will help you navigate each stage with confidence.
The first step in the diagnosis and evaluation process is a thorough clinical assessment. Pheochromocytomas typically secrete excess catecholamines, leading to a classic triad of episodic headache, sweating, and palpitations. However, presentations can be highly variable, and many patients are identified incidentally during imaging for unrelated reasons.
During the physical exam, clinicians look for signs that may suggest catecholamine excess, such as a rapid heart rate, tremor, or orthostatic hypotension after an episode. Blood pressure should be measured in both sitting and standing positions, and a 24‑hour ambulatory monitor may be employed to capture fluctuations.
Baseline blood work includes complete blood count, metabolic panel, and renal function tests to assess overall health before more specific investigations.
These baseline studies set the stage for targeted biochemical testing, the cornerstone of confirming a pheochromocytoma.
Precise biochemical assessment is the most reliable method for confirming the presence of a catecholamine‑producing tumor. The diagnosis and evaluation protocol at Liv Hospital follows international guidelines, employing both plasma and urinary measurements to maximize sensitivity.
Blood is drawn after the patient has rested supine for at least 30 minutes. Elevated plasma free metanephrine or normetanephrine levels are highly sensitive, detecting more than 95% of pheochromocytomas.
Patients collect all urine over a full day, which is then analyzed for catecholamines (epinephrine, norepinephrine, dopamine) and their metabolites. This test is especially useful when plasma sampling is not feasible.
When biochemical results are unequivocal, imaging studies are ordered to localize the tumor and assess its relationship to surrounding structures.
After confirming excess catecholamine production, the next phase of diagnosis and evaluation focuses on precise tumor localization. Multiple imaging techniques are integrated to provide a comprehensive map for surgical planning.
Contrast‑enhanced CT offers high spatial resolution and is the first‑line modality for most patients. Typical findings include a well‑defined, hypervascular mass in the adrenal gland or extra‑adrenal paraganglion.
MRI is preferred for patients with contraindications to iodinated contrast or for detecting lesions in the pelvis and abdomen where CT may be limited. T2‑weighted images often reveal a “light‑bulb bright” signal characteristic of pheochromocytoma.
When anatomical imaging is inconclusive, functional studies such as ¹²³I‑metaiodobenzylguanidine (MIBG) scintigraphy, ⁶⁸Ga‑DOTATATE PET/CT, or ¹⁸F‑FDG PET provide metabolic information and can identify metastatic disease.
The combination of anatomical and functional imaging ensures that surgeons receive a three‑dimensional roadmap, reducing intra‑operative surprises.
Approximately 30–40% of pheochromocytomas are linked to germline mutations, making genetic testing a vital component of comprehensive diagnosis and evaluation. Identifying an inherited syndrome influences not only patient management but also family screening.
Liv Hospital’s molecular laboratory screens for mutations in RET, VHL, NF1, SDHx (SDHA, SDHB, SDHC, SDHD), TMEM127, and MAX. Next‑generation sequencing panels allow rapid, comprehensive analysis.
Patients with SDHB mutations, for example, have a higher risk of malignant transformation and may require more aggressive surveillance. Genetic counseling is offered before and after testing to discuss implications for the patient and relatives.
Accurate diagnosis and evaluation demands careful differentiation of pheochromocytoma from other conditions that can produce similar biochemical or imaging findings.
Repeat biochemical testing after withdrawal of interfering medications, combined with targeted imaging, helps rule out false positives. In ambiguous cases, a multidisciplinary tumor board reviews all data before finalizing the diagnosis.
Once the tumor is localized and the genetic background understood, the final phase of diagnosis and evaluation transitions to treatment planning. A coordinated approach ensures patient safety during pre‑operative preparation, surgery, and postoperative follow‑up.
Patients receive α‑adrenergic blockade (e.g., phenoxybenzamine) for 10–14 days to control blood pressure and expand intravascular volume, followed by β‑blockade if tachycardia persists. Close monitoring in an intensive care setting is standard.
After tumor removal, plasma metanephrines are measured at 2 weeks, 6 months, and annually to detect recurrence. Lifelong surveillance is recommended for patients with germline mutations.
Liv Hospital combines JCI accreditation, a multilingual care team, and state‑of‑the‑art diagnostic facilities to deliver world‑class management of pheochromocytoma. International patients benefit from seamless coordination of appointments, interpreter services, and accommodation assistance, ensuring a stress‑free experience from first consultation through recovery.
Ready to schedule your comprehensive evaluation? Contact our dedicated international patient office today to arrange a personalized consultation and take the first step toward safe, expert care.
Liv Hospital Ulus
Assoc. Prof. MD. Seda Turgut
Endocrinology and Metabolism
Liv Hospital Ulus
Prof. MD. Demet Yetkin
Endocrinology and Metabolism
Liv Hospital Vadistanbul
Prof. MD. Berçem Ayçiçek
Endocrinology and Metabolism
Liv Hospital Vadistanbul
Prof. MD. Gönül Çatlı
Pediatric Endocrinology
Liv Hospital Vadistanbul
Prof. MD. Kubilay Ükinç
Endocrinology and Metabolism
Liv Hospital Bahçeşehir
Assoc. Prof. MD. Sevil Arı Yuca
Pediatric Endocrinology and Metabolic Diseases
Liv Hospital Bahçeşehir
Assoc. Prof. MD. Ufuk Özuğuz
Endocrinology and Metabolism
Liv Hospital Bahçeşehir
Spec. MD. Hüseyin Çelik
Endocrinology and Metabolism
Liv Hospital Topkapı
Prof. MD. Mehmet Aşık
Endocrinology and Metabolism
Liv Hospital Topkapı
Prof. MD. Nujen Çolak Bozkurt
Endocrinology and Metabolism
Liv Hospital Ankara
Prof. MD. Banu Aktaş Yılmaz
Endocrinology and Metabolism
Liv Hospital Ankara
Prof. MD. Peyami Cinaz
Pediatric Endocrinology
Liv Hospital Ankara
Prof. MD. Serdar Güler
Endocrinology and Metabolism
Liv Hospital Ankara
Spec. MD. Elif Sevil Alagüney
Endocrinology and Metabolism
Liv Hospital Gaziantep
Prof. MD. Zeynel Beyhan
Endocrinology and Metabolic Diseases
Liv Hospital Gaziantep
Spec. MD. Tahsin Özenmiş
Endocrinology and Metabolism
Liv Hospital Samsun
Assoc. Prof. MD. Gülçin Cengiz Ecemiş
Endocrinology and Metabolism
Liv Hospital Samsun
Spec. MD. Esra Tutal
Endocrinology and Metabolic Diseases
Liv Bona Dea Hospital Bakü
MD. FİDAN QULU
Endocrinology and Metabolism
Spec. MD. Zümrüt Kocabey Sütçü
Pediatric Endocrinology
Liv Hospital Ulus + Liv Hospital Vadistanbul + Liv Hospital Topkapı
Prof. MD. Cengiz Kara
Pediatric Endocrinology
Send us all your questions or requests, and our expert team will assist you.
Pheochromocytoma typically secretes excess catecholamines, leading to a characteristic triad of sudden, severe headache, profuse sweating unrelated to temperature, and palpitations or tachycardia. Patients may also experience sustained high blood pressure, panic‑like episodes, and sometimes anxiety or tremor. Because the presentation can be variable, incidental discovery on imaging for unrelated reasons is also common. Recognizing these signs early is crucial to prevent hypertensive crises and guide further testing.
Confirmation relies on measuring catecholamine metabolites. Plasma free metanephrine and normetanephrine levels, drawn after the patient rests supine for 30 minutes, have >95% sensitivity. A 24‑hour urine collection for catecholamines (epinephrine, norepinephrine, dopamine) and their metabolites provides an alternative when plasma sampling is impractical. Values exceeding twice the upper reference limit are diagnostic; intermediate elevations warrant repeat testing or imaging. Medication review is essential to avoid false‑positives from agents like tricyclic antidepressants.
After biochemical confirmation, anatomical imaging begins with contrast‑enhanced CT, which offers rapid, high‑resolution visualization of adrenal or extra‑adrenal masses. MRI is preferred for patients who cannot receive iodinated contrast or when lesions are in the pelvis/abdomen; T2‑weighted images often show a bright “light‑bulb” signal. When CT/MRI are inconclusive, functional studies such as ¹²³I‑MIBG scintigraphy, ⁶⁸Ga‑DOTATATE PET/CT, or ¹⁸F‑FDG PET provide metabolic information and can detect metastatic disease. Combining modalities yields a precise three‑dimensional map for surgery.
Approximately one‑third of pheochromocytomas are hereditary. Indications for germline testing include age < 45 years at diagnosis, bilateral or multifocal tumors, extra‑adrenal (paraganglioma) location, a known family history of endocrine neoplasia, or co‑existing tumors such as medullary thyroid carcinoma. Liv Hospital screens for mutations in RET, VHL, NF1, SDHx genes, TMEM127, and MAX using next‑generation sequencing panels. Identifying a mutation guides surveillance intensity, informs surgical strategy (e.g., adrenal‑sparing), and enables cascade testing for relatives.
To prevent intra‑operative hypertensive crises, patients are started on an α‑adrenergic blocker such as phenoxybenzamine (or a selective agent like doxazosin) for 10–14 days to control blood pressure and expand intravascular volume. Once adequate α‑blockade is achieved, a β‑blocker may be added to manage persistent tachycardia, but never before α‑blockade to avoid unopposed α‑stimulation. Close monitoring in an intensive‑care setting, with fluid management and electrolyte balance, is standard practice before proceeding to surgery.
The centre’s international patient office streamlines the diagnostic journey for patients traveling from abroad. Services include a multilingual care team, professional medical interpreters, a single point of contact for scheduling labs, imaging, and consultations, and assistance with travel logistics, visas, and hotel arrangements. All documentation is provided in the patient’s preferred language, ensuring clear communication throughout the evaluation and treatment planning phases.
CT provides rapid acquisition, excellent anatomic detail, and is the first‑line modality for most patients; however, it involves ionizing radiation and may miss small extra‑adrenal lesions. MRI does not use radiation and delivers superior soft‑tissue contrast, making it ideal for patients with iodinated‑contrast allergy, renal insufficiency, or when evaluating pelvic/abdominal lesions. MRI’s T2‑weighted “light‑bulb” signal is characteristic of pheochromocytoma. The choice depends on patient factors, availability, and the need for detailed tissue characterization.
Certain drugs (e.g., tricyclic antidepressants, labetalol, decongestants) can elevate catecholamine metabolites, leading to false‑positives. A thorough medication review and temporary discontinuation of interfering agents, when safe, are mandatory before sampling. Patients should be rested supine for plasma tests and avoid strenuous activity, caffeine, and nicotine. If results are only mildly elevated, repeat testing or confirmatory imaging is recommended to rule out spurious findings.
Post‑operative monitoring includes measuring plasma free metanephrines at 2 weeks to confirm biochemical cure, followed by assessments at 6 months and yearly thereafter. Patients with germline mutations (e.g., SDHB) require lifelong surveillance due to higher recurrence risk, often incorporating periodic imaging and biochemical testing. Clinical follow‑up also assesses blood pressure normalization and adrenal cortical function, especially after partial adrenal‑sparing procedures.
BlogEndocrinologyApr 13, 2026Discover the definition, symptoms, and hormone secretion of pheochromocytoma (pheo), a rare tumor that can ...
BlogEndocrinologyApr 13, 2026Discover the latest treatments for pheochromocytoma, including alpha and beta blockers. Learn what ADH stan...
BlogEndocrinologyApr 13, 2026Explore the 7 key symptoms of pituitary hypothalamic pheochromocytoma, a rare neuroendocrine tumor. Learn a...
BlogEndocrinologyApr 13, 2026Learn the key facts about what happens when you're on your period. Our guide provides insights into the dia...
BlogEndocrinologyApr 13, 2026Learn the role of alpha blockers in treating pheochromocytoma, a rare adrenal gland tumor. Our comprehensiv...
BlogEndocrinologyApr 13, 2026Discover the common symptoms of adrenal gland masses in women, including fatigue, weight changes, and hormo...
Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.
Start Chat on WhatsApp or call us at +90 530 174 28 17